Clinical trials: Alpha-Gal Syndrome, open to volunteers
Alpha-Gal Syndrome
The α-gal Syndrome - Investigating Immune Reactions to Tick Bites
Tick bites can transmit pathogens, but they can also induce a food allergy to mammalian meat. The goal of this clinical trial is to follow immune response and antibody build-up in individuals bitten by a tick.
- Trial name
- ImmunoGal (NCT07177729)
- Where
- 2 sites in Luxembourg
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Post-tick Bite Illness, Mast Cell Stabilizer
Mast Cell Treatment in Post-tick Bite Illness (PTBI)
This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with…
- Trial name
- NCT07526558
- Testing
- Ketotifen, fexofenadine, Cromolyn Sodium
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Alpha-Gal Syndrome, Allergy
Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG
This is a multisite, randomized, double-blind, controlled cross-over trial with detailed characterization of participants with varying clinical sub-phenotypes of Alpha-gal Syndrome (AGS) who are then evaluated by oral food…
- Trial name
- BeACON4AG (NCT07611435)
- Testing
- DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clonal Mast Cell Disease, KIT D816V Mutation
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
- Conditions
- Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
- Trial name
- POLARIS (NCT07143669)
- Testing
- Screening
- Where
- 26 sites in United States, Belgium
- Volunteers
- 750 people
- Sponsor
- Blueprint Medicines Corporation